In short
This article discusses clinical trials investigating the use of ExPEC9V vaccine, which contains the active substance ECOO2, for preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease in adults aged 60 and older. The trials aim to assess the vaccine's efficacy, safety, and immune response, particularly in individuals with a history of urinary tract infections.
At a glance
- Vaccine Name
- ExPEC9V (JNJ-78901563)
- Key Active Substance
- ECOO2 (among others)
- Target Population
- Adults aged 60+ with history of UTIs
- Primary Objectives
- Prevent invasive E. coli disease, assess efficacy and safety
- Administration
- Intramuscular injection
- Dose
- 88 μg (micrograms)
- Trial Phase
- Phase 3
- Key Outcomes Measured
- IED events, UTIs, immunogenicity, safety
What is ECOO2?
ECOO2 is one of the active components in a new vaccine called ExPEC9V (also known as JNJ-78901563) that is currently being developed to prevent invasive diseases caused by certain types of Escherichia coli bacteria. This vaccine is designed to protect against multiple strains of E. coli that can cause serious infections outside the intestines.
What Disease Does ECOO2 Target?
The ExPEC9V vaccine, which includes ECOO2, is aimed at preventing invasive extraintestinal pathogenic Escherichia coli (ExPEC) disease. This term refers to serious infections caused by E. coli bacteria that occur outside the intestines. These can include:
- Urinary tract infections (UTIs): Infections of the bladder, kidneys, or other parts of the urinary system
- Bloodstream infections (bacteremia): When bacteria enter the bloodstream
- Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation
- Other infections in normally sterile body sites
These infections can be particularly dangerous in older adults or people with weakened immune systems.
How Does ECOO2 Work?
ECOO2 is part of a vaccine that targets specific types (serotypes) of E. coli bacteria. The vaccine contains components that mimic parts of the bacteria's outer surface. When injected, these components stimulate the immune system to produce antibodies against these specific E. coli strains. This prepares the body to fight off these bacteria if encountered in the future, potentially preventing invasive infections.
Current Clinical Trials
ECOO2, as part of the ExPEC9V vaccine, is currently being studied in Phase 3 clinical trials. These are large-scale studies designed to confirm the vaccine's effectiveness and safety. Two notable trials are:
- A study evaluating the vaccine alongside a high-dose influenza vaccine in adults 65 years and older.
- A study focusing on adults 60 years and older with a history of urinary tract infections.
These trials aim to determine how well the vaccine prevents invasive E. coli infections and assess its safety profile.
Who Can Receive ECOO2?
While ECOO2 is still in clinical trials and not yet approved for general use, the current studies focus on older adults, particularly those at higher risk of E. coli infections. The main groups being studied include:
- Adults aged 65 years and older
- Adults aged 60 years and older with a history of urinary tract infections
- People with additional risk factors for invasive E. coli disease, such as a history of hospitalization or certain medical conditions
How is ECOO2 Administered?
The ExPEC9V vaccine, which contains ECOO2, is administered as an intramuscular injection. This means it's injected directly into a muscle, typically in the upper arm (deltoid muscle). In the current clinical trials, participants receive a single dose of the vaccine.
Safety and Efficacy
As ECOO2 is still in clinical trials, comprehensive safety and efficacy data are not yet available. The ongoing Phase 3 studies are designed to evaluate:
- How effective the vaccine is at preventing invasive E. coli infections
- The vaccine's safety profile, including any side effects
- How well the vaccine stimulates the immune system to produce antibodies against the targeted E. coli strains
The trials will also assess the vaccine's impact on participants' quality of life and overall health status.
Future Prospects
If the current clinical trials show positive results, ECOO2 as part of the ExPEC9V vaccine could become an important tool in preventing serious E. coli infections, especially in older adults and those at higher risk. This could potentially reduce hospitalizations, improve quality of life, and even save lives by preventing severe infections like sepsis.
However, it's important to remember that the vaccine is still in the testing phase. More data from the ongoing trials will be needed to fully understand its effectiveness and safety profile before it can be considered for approval and widespread use.